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February 21, 2006:884–92estricted to secondary CVD events during the first year after
ischarge from rehab and which had included coronary artery
evascularization procedures besides myocardial infarction, stroke,
nd CVD death as end points, we also had observed a decreased
isk in patients who never smoked (odds ratio [OR]  0.44), who
eported former smoking (OR  0.64), and who were categorized
s recent quitters (OR  0.71) in comparison with continued
mokers. The current study, which is based on a much longer
ollow-up, an exclusive focus on “hard” disease endpoints, and the
se of repeated measurements of smoking status, suggests that
ertinent risk reductions may be even stronger in the long run.
The proportions of cotinine-positive subjects in the group of
elf-reported never smokers at rehab (6%) and at one-year
ollow-up (9%) may serve as estimates for the proportion of
eceivers (persons misreporting their smoking status). Although
alse-positive test results cannot be ruled out, exposure to environ-
ental tobacco smoke, which may have a major impact on
rognosis, is unlikely to cause a serum cotinine level as high as our
utpoint (4). The finding that 20% of patients changed smoking
tatus in the first year of follow-up further underlines the
elatively high dynamics of smoking status shortly after the
ccurrence of CHD.
We conclude that the impact of smoking abstinence on long-
erm prognosis of patients with CHD may be considerably larger
han suggested by previous studies which relied on self-reports of
moking status. Our results underline the importance of efforts to
upport smoking cessation and to prevent relapse in patients with
oronary heart disease.
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nti-Inflammatory Action of
ngiotensin-Converting Enzyme Inhibitors
nd Angiotensin Receptor Blockers
he meta-analysis by Healey et al. (1) indicated that both
ngiotensin-converting enzyme inhibitors (ACEIs) and angioten-
in receptor blockers (ARBs) appear to be effective in the preven-
ion of atrial fibrillation. However, among the plausible underlying
echanisms, they did not mention the potential role of low-grade
ystemic inflammation.
Increasing levels of C-reactive protein (CRP), the classic marker
f systemic inflammation, have been shown to be associated with
trial fibrillation (2,3). Furthermore, CRP appears also to predict
atients at increased risk for developing future atrial fibrillation (4).
Because angiotensin receptor blockade has been shown to be
elated to a decrease in markers of systemic inflammation (5,6),
his anti-inflammatory action may help explain the beneficial effect
f ACEIs and ARBs in the prevention of atrial fibrillation.
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revention of Atrial Fibrillation by
ngiotensin-Converting Enzyme Inhibitors
nd Angiotensin II Receptor Blockers
e read with great interest the report by Healey et al. (1) in which
hey presented a meta-analysis of published randomized trials involv-
ng the prevention of atrial fibrillation (AF) with angiotensin-
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February 21, 2006:884–92onverting enzyme inhibitors (ACEIs) and angiotensin II receptor
lockers (ARBs). The investigators present a number of highly
lausible hypotheses to explain the potential mechanisms by which
he renin-angiotensin-aldosterone system (RAAS) blockade with
hese agents might reduce the burden of AF, such as antiarrhyth-
ic effects and reversed cardiac remodeling by left ventricular
ypertrophy regression and reduced left atrial stretch.
We would like to offer additional pathophysiological insights
nto the benefits of these drugs on AF and its complications. First,
here is mounting evidence to support an association between
nflammation and AF. For example, atrial biopsies taken from
atients in AF have demonstrated evidence of inflammatory
nfiltrates within the atrial tissue (2,3). Furthermore, consistent
inks exist between inflammatory markers, such as C-reactive
rotein (CRP), tumor necrosis factor-alpha (TNF-), interleukin
IL)-6, white cell count, and the presence/development of AF. It
s also clear that angiotensin (ang) II has several proinflammatory
roperties (4). For example, ang II can act locally as a chemokine
nd inflammatory molecule, increasing the production of several
roinflammatory cytokines (e.g., IL-6 and TNF-), adhesion
olecules (such as vascular cell adhesion molecule-1 [VCAM-1]
n endothelial cells, intracellular adhesion molecule [ICAM]-1
nd osteopontin, a known macrophage chemotactic and adhesion
olecule), chemoattractant protein (MCP)-1 (further increasing
onocyte recruitment), and various selectins (such as P-selectin
nd s-selectin, leading to leukocyte tethering and rolling) (5–8).
There is also histological evidence to confirm that AF (both
ersistent and paroxysmal) can lead to increased ang II receptor
xpression (9). In a key study, Cardin et al. were able to link
ncreased atrial expression of ang II receptors with increased atrial
ell death and leukocyte infiltration, again supporting a potential
ink among the RAAS, inflammation, and AF (10). It would also
ppear that the relationship between ang II and inflammation is
eciprocal, as not only does ang II cause inflammation, but the
onverse is also true with inflammation itself acting as a stimulus
or increased ang II production.
Moreover, RAAS blockade influences the complications asso-
iated with AF; also, AF confers a hypercoagulable state, even in
he absence of underlying heart disease; abnormalities of hemo-
tasis, fibrinolysis, endothelium, and platelets have all been de-
cribed in this arrhythmia, which may increase the risk of stroke
nd thromboembolism (11). Furthermore, there is an established
ink among inflammation, AF, and thrombosis (12). Indeed, ang II
as known prothrombotic properties, and in the AF substudy of
he Losartan Intervention For End Point Reduction in Hyperten-
ion (LIFE) trial, a significant reduction occurred in stroke among
osartan- versus atenolol-treated AF patients, despite equivalent
lood pressure reduction (13).
Finally, there appears to be prevailing links between AF and
nflammation, thrombosis, and angiotensin II activation. Conse-
uently, RAAS blockade (by ACEIs and ARBs), with subsequent
eduction in AF burden and its complications, is consistent with
he reduction in the inflammatory and prothrombotic substrate
elated to AF.
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EPLY
ased on a growing body of evidence implicating inflammation in
he development of atrial fibrillation (AF) (1–3), Drs. Mascitelli,
ezzetta, Boos, and Lip have postulated that angiotensin-
onverting enzyme (ACE) inhibitors and angiotensin receptor
lockers (ARB) may prevent AF by reducing inflammation. We
gree that this is a plausible mechanism for AF prevention,
articularly because a recent randomized-controlled trial has found
hat systemic corticosteroids reduce both C-reactive protein and
he rate of recurrent AF in patients following cardioversion (2).
owever, none of the trials included in our meta-analysis (4)
ontained data on inflammatory markers; thus, we did not make
his potential mechanism a focus of our discussion. Instead, we
xamined available trial data, such as the class of medication
valuated and the patient group studied, in an attempt to explain
he significant heterogeneity in the results of individual trials (4).
